GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:
Cantor Global Healthcare Conference
Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m. ET
Webcast Link: Click Here
H.C. Wainwright 27th Annual Global Investment Conference
Format: Presentation and 1x1 Meetings
Presentation Date and Time: Wednesday, September 10, 2025, 9:30 a.m. ET
Webcast Link: Click Here
Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Format: 1x1 Meetings
Date: Thursday, September 11, 2025
Institutional investors interested in scheduling a meeting may contact their Cantor, H.C. Wainwright, or Lake Street representative or email This email address is being protected from spambots. You need JavaScript enabled to view it..
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
This press release was published by a CLEAR® Verified individual.
Last Trade: | US$1.22 |
Daily Change: | -0.06 -4.69 |
Daily Volume: | 217,104 |
Market Cap: | US$46.460M |
September 04, 2025 July 01, 2025 May 28, 2025 May 08, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load